Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169,324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Barriers to Clinical Trial Implementation Among Community Care Centers.
Ebrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia NJ, Zengin ZB, Meza L, Chawla N, Castro DV, Dizman N, Bhagat R, Liv S, Li X, Rock A, Liu S, Tripathi A, Dorff T, Oyer RA, Boehmer L, Pal S, Chehrazi-Raffle A. Ebrahimi H, et al. Among authors: li x. JAMA Netw Open. 2024 Apr 1;7(4):e248739. doi: 10.1001/jamanetworkopen.2024.8739. JAMA Netw Open. 2024. PMID: 38683608 Free PMC article.
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.
Castro DV, Prajapati SR, Feng MI, Chan EH, Lee KO, Paul T, Sehgal I, Patel J, Li X, Zengin ZB, Ebrahimi H, Govindarajan A, Meza L, Mercier BD, Chawla NS, Dizman N, Philip EJ, Hsu J, Bergerot CD, Chehrazi-Raffle A, Rock A, Liu S, Tripathi A, Dorff TB, Pal SK. Castro DV, et al. Among authors: li x. BJU Int. 2024 Mar;133(3):297-304. doi: 10.1111/bju.16148. Epub 2023 Sep 1. BJU Int. 2024. PMID: 37548533
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.
Chehrazi-Raffle A, Leong S, Ali S, Kim T, Melamed S, Li X, Zengin Z, Meza L, Chawla N, Govindarajan A, Castro D, Mercier B, Ebrahimi H, Dizman N, Tripathi N, Sayegh N, Rock A, Yeh J, Pal SK, Onyshchenko M. Chehrazi-Raffle A, et al. Among authors: li x. Oncologist. 2023 Dec 11;28(12):1079-1084. doi: 10.1093/oncolo/oyad190. Oncologist. 2023. PMID: 37432304 Free PMC article.
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations.
Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan BL, Pal SK. Gebrael G, et al. Among authors: li x, li h. Eur Urol Focus. 2024 Apr 4:S2405-4569(24)00050-6. doi: 10.1016/j.euf.2024.03.006. Online ahead of print. Eur Urol Focus. 2024. PMID: 38580524
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.
Dizman N, Govindarajan A, Zengin ZB, Meza L, Tripathi N, Sayegh N, Castro DV, Chan EH, Lee KO, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal SK. Dizman N, et al. Among authors: li x. Clin Genitourin Cancer. 2023 Oct;21(5):530-536. doi: 10.1016/j.clgc.2023.06.004. Epub 2023 Jun 25. Clin Genitourin Cancer. 2023. PMID: 37495481
169,324 results
You have reached the last available page of results. Please see the User Guide for more information.